UK trials show experimental Novavax coronavirus vaccine is 89.3% effective
Published
UK phase three trials of the experimental Novavax COVID-19 vaccine have found it demonstrated 89.3% efficacy against the virus.
Full ArticlePublished
UK phase three trials of the experimental Novavax COVID-19 vaccine have found it demonstrated 89.3% efficacy against the virus.
Full ArticleThe vaccine is the first to show in trials that it is effective against the UK variant of the virus.